NuPathe Inc. (NASDAQ: PATH) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for its migraine patch (Zelrix). PATH shares plunged to $2.06 at pre-market trading hours.
PATH traded over 5.7M shares compared to 204K 10day average volume.
Our Twitter followers alert of PSH’s entry on PATH at $2.10. We took a profit at $2.76 for the over 30% in daily gains. Don’t miss our next day-trading alert!
NuPathe Inc.
227 Washington Street
Suite 200
Conshohocken, PA 19428
Phone: 484.567.0130
Fax: 484.567.0136
NuPathe Inc. a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders.